Related Experiment Video

Updated: Nov 22, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors

Georgia Gomatou1, Ioannis Trontzas2, Stephanie Ioannou2

  • 1Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. georgia.gomatou@gmail.com.

Molecular Biology Reports
|January 7, 2021
PubMed

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors are used for metastatic breast cancer, but resistance develops. Understanding resistance mechanisms is key to developing new treatments and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a significant advancement in treating metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
  • Despite initial efficacy, most patients develop resistance to CDK4/6 inhibitors, necessitating research into underlying mechanisms.

Purpose of the Study:

  • To review and synthesize current understanding of resistance mechanisms to CDK4/6 inhibitors in breast cancer.
  • To identify potential therapeutic strategies to overcome or prevent resistance.

Main Methods:

  • Literature review of studies investigating resistance to CDK4/6 inhibitors.
  • Analysis of molecular mechanisms contributing to treatment failure.
  • Exploration of potential combination therapies.

Main Results:

  • Resistance mechanisms involve cell cycle dysregulation, including loss of retinoblastoma function, CDK6 overexpression, cyclin E upregulation, and CDK7 overexpression.
  • Aberrations in signaling pathways, particularly the PI3K/AKT/mTOR pathway, are implicated in resistance.
  • Potential overlap exists between endocrine resistance and CDK4/6 inhibitor resistance mechanisms.

Conclusions:

  • Understanding the diverse mechanisms of resistance is crucial for managing patients progressing on CDK4/6 inhibitors.
  • Combinational therapeutic strategies are essential to prevent resistance and optimize treatment outcomes.
Keywords:
Breast CancerCDK 4/6 inhibitorsCyclin-dependent kinaseResistance

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.2K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
120.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.5K